Conditioned media experiments confirmed that PAI-1-depleted or lucanthone- and combination-treated glioma cells promote a pro-inflammatory phenotype in microglia, further supporting the immunomodulatory potential of this therapeutic strategy. This evidence concerns the gene SERPINE1 and glioma.